|
|
Eli Lilly And Company (LLY) |
|
|
|
| |
LLY's Operating Income Growth by Quarter and Year
Eli Lilly And's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| LLY Operating Income (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
-
|
1,917.20
|
1,992.10
|
1,400.20
|
| III Quarter |
September |
-
|
1,881.20
|
1,278.30
|
1,430.70
|
| II Quarter |
June |
-
|
1,403.40
|
1,196.80
|
1,498.30
|
| I Quarter |
March |
2,404.30
|
1,155.30
|
1,590.80
|
645.10
|
| FY |
|
2,404.30
|
6,357.10
|
6,058.00
|
4,974.30
|
| LLY Operating Income first quarter 2022 Y/Y Growth Comment |
Eli Lilly And Company achieved in the first quarter 2022, above Company average Operating Income surge of 108.11% year on year, to $ 2,404.30 millions.
According to the results reported in the first quarter 2022, Eli Lilly And Company achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Eli Lilly And Company' s Operating Income doubling of 108.11% ranks overall at the positon no. 54 in the first quarter 2022.
Explain Operating Income growth
|
| LLY Operating Income ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
-3.76 % |
42.27 % |
343.8 % |
| III Quarter |
September |
- |
47.16 % |
-10.65 % |
0.3 % |
| II Quarter |
June |
- |
17.26 % |
-20.12 % |
- |
| I Quarter |
March |
108.11 % |
-27.38 % |
146.6 % |
-53.03 % |
| FY |
|
- |
4.94 % |
21.79 % |
61.39 % |
LLY Operating Income (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
1.91 % |
55.84 % |
-2.13 % |
| III Quarter |
September |
- |
34.05 % |
6.81 % |
-4.51 % |
| II Quarter |
June |
- |
21.47 % |
-24.77 % |
132.26 % |
| I Quarter |
March |
25.41 % |
-42.01 % |
13.61 % |
104.47 % |
| FY (Year on Year) |
|
- |
4.94 % |
21.79 % |
61.39 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 396.16 % |
9.62 % |
-37.37 % |
| (Dec. 31, 2009) |
|
(Jun 30 2018) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 396.16 % |
9.62 % |
-37.37 % |
| (Dec. 31, 2009) |
|
(Jun 30 2018) |
|
| Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Eli Lilly And's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 2642.73 % |
57.79 % |
-94.74 % |
| (Jun 30 2017) |
|
|
| LLY's I. Quarter Q/Q Operating Income Comment |
Eli Lilly And Company achieved in the I. Quarter 2022 below company average Operating Income jump of 25.41% quarter on quarter, to $ 2,404.30 millions.
I. Quarter 2022 Operating Income sequential growth seem to be contradictory, although beneath the regular, yet it shows a quite recovery relative to the -42.01% in the I. Quarter 2021.
Within Major Pharmaceutical Preparations industry Eli Lilly And Company achieved highest sequential Operating Income growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 113. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 2642.73 % |
57.79 % |
-94.74 % |
| (Jun 30 2017) |
|
|
| LLY's I. Quarter Q/Q Operating Income Comment |
Eli Lilly And Company achieved in the I. Quarter 2022 below company average Operating Income jump of 25.41% quarter on quarter, to $ 2,404.30 millions.
Albeit the I. Quarter 2022 LLY's Operating Income quarter on quarter growth was beneath the regular , it has been still promising news, as the I. Quarter improvement, transcends the -42.01% Operating Income growth in the I. Quarter a year ago
Within Major Pharmaceutical Preparations industry Eli Lilly And Company achieved highest sequential Operating Income growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 113. |
|
Eli Lilly And's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
12 Months Ending
(Sep 30 2021) |
12 Months Ending
(Jun 30 2021) |
12 Months Ending
(Mar 31 2021) |
| Cumulative Operating Income 12 Months Ending |
$ 7,606.10 |
$ 6,357.10 |
$ 6,432.00 |
$ 5,829.10 |
$ 5,622.50 |
| Y / Y Operating Income Growth (TTM) |
35.28 % |
4.94 % |
17.67 % |
3.75 % |
-5.03 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 184 |
# 672 |
# 1269 |
# 726 |
# 1365 |
| Seqeuential Operating Income Change (TTM) |
19.65 % |
-1.16 % |
10.34 % |
3.67 % |
-7.19 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 54 |
# 700 |
# 908 |
# 1663 |
# 1943 |
| Cumulative Operating Income growth
Comment |
Eli Lilly And saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 35.28% year on year, to $ 7,606 millions if the fiscal year would have ended in Mar 31 2022.
Eli Lilly And's trailing twelve months Operating Income growth was higher than company's average 14.97% and higher than 4.94% growth in Dec 31 2021. And, Eli Lilly And realized the fastest Operating Income growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period increase was slower at 19.65 % from $6357.1 millions reported in twelve months ending a quarter Dec 31 2021.
Still it was validation of positive momentum, as the typical Q/Q TTM gain stands at 9.62%.
The growth was much higher from twelve months ended Dec 31 2021 exhibited at 19.65 % increase from $6357.1 millions in twelve months ending a quarter before.
Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 184, from total ranking in previous quarter at 672. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
396.16 % |
9.62 % |
-37.37 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
458.23 % |
14.97 % |
-62.4 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 1 |
| Sector |
# 1 |
| S&P 500 |
# 54 |
|
| Cumulative Operating Income growth
Comment |
Eli Lilly And saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 35.28% year on year, to $ 7,606 millions if the fiscal year would have ended in Mar 31 2022.
Eli Lilly And's trailing twelve months Operating Income growth was higher than company's average 14.97% and higher than 4.94% growth in Dec 31 2021. And, Eli Lilly And realized the fastest Operating Income growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period rise was beneth at 19.65 % from $6357.1 millions reported in twelve months ending a quarter before Xavier Edwards continued.
Still this was confirmation of convincing trend, as the average sequential gain is at 9.62%.
The growth was even more impressive from twelve months ended Dec 31 2021 showed at 19.65 % rise from $6357.1 millions in twelve months ending a quarter before.
Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 184, from total ranking in previous quarter at 672. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
396.16 % |
9.62 % |
-37.37 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
458.23 % |
14.97 % |
-62.4 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 1 |
| Sector |
# 1 |
| S&P 500 |
# 54 |
|
176.85%